14-3-3η amplifies androgen receptor actions in prostate cancer

Clinical Cancer Research

Volumn 15, Issue 24, 2009, Pages 7571-7581

  Titus, Mark A ^a,b   Tan, Jiann An ^a   Gregory, Christopher W ^a,e   Ford, O Harris ^a   Subramanian, Romesh R ^d,f   Fu, Haian ^d   Wilson, Elizabeth M ^a   Mohler, James L ^a,b,c   French, Frank S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Clinsys Clinical Research   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; MITOGENIC AGENT; PROTEIN; PROTEIN 14 3 3; PROTEIN 14 3 3 ETA; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER RECURRENCE; CASTRATION; CELL FREE SYSTEM; CELL NUCLEUS; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR BINDING; TISSUE MICROARRAY; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT;

EID: 73349110927     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1976     Document Type: Article

References (59)

1. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-65.
2. de Vere White R, Meyers F, Chi SG, et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997;31:1-6.
3. Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998; 35:63-70.
4. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068-72.
5. Kim D, Gregory CW, French FS, Smith GW, Mohler JL. Androgen receptor expression and cellular proliferation during transition from androgen dependent to recurrent growth in the CWR22 Prostate Cancer Xenograft. Am J Pathol 2002;160:219-26.
6. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25: 276-308.
7. Gregory CW, Hamil KG, Kim D, et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58:5718-24.
8. Mousses JL, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20:6718-23.
9. Visakorpi T, Hytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene in progression of human prostate cancer. Nat Genet 1995;9:401-6.
10. Tan J-A, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptor expressed in the androgen-dependent human prostate cancer xenograph CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-9.
11. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
12. Mohler JL, Gregory CG, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
13. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
14. Grossman ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 2001;93: 1687-97.
15. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
16. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002;9:61-73.
17. Scher HI, Sawyers Cl. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
18. Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 2000;40:617-47.
19. Yaffe MB, Elia AEH. Phosphoserine/threoninebinding domains. Curr Opin Cell Biol 2001;13: 131-38.
20. Muslin AJ, Xing H. 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal 2000;12:703-9.
21. Tzivion G, Shen YH, Zhu J. 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene 2001;20:6331-38.
22. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003;3:931-43.
23. Wainstein MA, He F, Robinson D, et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-52.
24. Myers RB, Oelschlager DK, Coan PN, et al. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma. J Urol 1999;161:945-9.
25. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8.
26. Zhang L, Wang H, Liu D, Liddington R, Fu H. Raf-1 kinase and exoenzyme S interact with 14-3-3ζ through a common site involving lysine 49. J Biol Chem 1997;272:13717-24.
27. Gregory CW, Fei X, Ponguta LA, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279:7119-30.
28. Titus MA, Gregory CW, Ford OH III, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-71.
29. Miyamoto KK, McSherry SA, Dent GA, et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 1993;149:1015-9.
30. Bai S, He B, Wilson EM. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 2005;25:1238-57.
31. Zilliacus J, Holter E, Wakui H, Tazawa H, Treuter E, Gustafsson JA. Regulation of glucocorticoid receptor activity by 14-3-3 dependent intracellular relocalization of the corepressor RIP140. Mol Endocrinol 2001;15:501-11.
32. Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol 2006;16:162-72.
33. Xing H, Zhang S, Weinheimer C, Kovacs A, Muslin AJ. 14-3-3 proteins block apoptosis and differentially regulate MAPK cascades. EMBO J 2000;19:349-58.
34. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999;96:5458-63.
35. Gregory CW, Whang YE, McCall W, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 2005;11:1704-12.
36. Liu Y, Majumder S, McCall W, et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005;65:3404-9.
37. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/ mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-9.
38. Quayle SN, Sadar MD. 14-3-3σ increases the transcriptional activity of the androgen receptor in the absence of androgens. Cancer Lett 2007; 254:137-45.
39. Tan J-A, Hall SH, Petrusz P, French FS. Thyroid receptor activator molecule, TRAM-1, is an androgen receptor coactivator. Endocrinology 2000;141:3440-50.
40. Ding XF, Anderson CM, Ma H, et al. Nuclear receptor binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator (SRC-1): multiple motifs with different binding specificities. Mol Endocrinol 1998;12:302-13.
41. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44.
42. Bin H, Wilson EM. Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol Cell Biol 2003;23:2135-50.
43. Carascossa S, Gobinet J, Georget V, et al. Receptor-interacting protein 140 is a repressor of the androgen receptor activity. Mol Endocrinol 2006;20:1506-18.
44. Tzivion G, Avruch J. 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 2002;277:3061-4.
45. Gardino AK, Smerdon SJ, Yaffe MB. Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol 2006;16:173-82.
46. Zhou ZX, Kemppainen JA, Wilson EM. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 1995;9:605-15.
47. Gioeli D, Black BE, Gordon V, et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 2006;20:503-15.
48. Wong HY, Burghoorn JA, Van Leeuwen M, et al. Phosphorylation of androgen receptor isoforms. Biochem J 2004;383:267-76.
49. Taneja SS, Ha S, Swenson NK, et al. Cellspecific regulation of androgen receptor phosphorylation in vivo. J Biol Chem 2005;280: 40916-24.
50. Haendler B, Schuttke I, Schleuning WD. Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3ç. Mol Cell Endocrinol 2001;173:63-73.
51. Myers RB, Oelschlager DK, Manne U, Coan PN, Weiss H, Grizzle WE. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma. Int J Cancer 1999;82:424-9.
52. Meehan KL, Sadar MD. Quantitative profiling of LNCaP prostate cancer cells using isotopecoded affinity tags and mass spectrometry. Proteomics 2004;4:1116-34.
53. Huang D, Liu X, Plymate SR, et al. Proteomic identification of 14-3-3σ as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12. Oncogene 2004;23:6881-9.
54. Yano M, Nakamuta S, Wu X, Okumura Y, Kido H. A novel function of 14-3-3 protein: 14-3-3ζ is a heat shock-related molecular chaperone that dissolves thermal-aggregated proteins. Mol Biol Cell 2006;17:4769-79, [Epub ahead of print].
55. Porter GW, Khuri FR, Fu H. Dynamic 14-3-3/ client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 2006;16:193-202.
56. Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 2006;16: 183-92.
57. Hoang AT, Huang J, Rudra-Ganguly N, et al. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol 2000;156:857-64.
58. Bin H, Bai S, Hnat AT, et al. An androgen receptor NH2-terminal motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem 2004;279:30643-53.
59. Dai Q, Zhang C, Wu Y, et al. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J 2003;22:5446-58.